Status:
RECRUITING
A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
Lead Sponsor:
Fu Xing Hospital, Capital Medical University
Conditions:
Retained Products of Conception
Miscarriage
Eligibility:
FEMALE
Brief Summary
The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vasc...
Eligibility Criteria
Inclusion Criteria:
- Recent history of miscarriage or delivery (within the past 8 weeks)
- Strong willingness to undergo conservative management
- Hemodynamically stable
- Signed informed consent form
Exclusion Criteria:
- Heavy vaginal bleeding (requiring immediate surgical intervention)
- Active pelvic or systemic infection (e.g., fever >38°C, elevated CRP/WBC)
- Severe dysfunction of vital organs (heart, liver, or kidney)
- Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
- Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)
- Placenta accreta spectrum disorders diagnosed during current pregnancy
- History of uterine artery embolization
Key Trial Info
Start Date :
October 23 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06862089
Start Date
October 23 2024
End Date
December 30 2026
Last Update
June 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hysteroscopy Center, Fuxing Hospital, Capital Medical University
Beijing, China, 100086